FDA Form 483

Regulatory Event

FDA investigator Camerson E. Moore of the Dallas District Office closed an eight-day inspection of QuVa Pharma, Inc.’s 503B outsourcing facility in Sugar Land, Texas on May 4, 2026, documenting three observations spanning aseptic contamination-prevention procedures, deviation investigation adequacy, and facility maintenance. The Form 483, issued to General Manager Sophia I. Flores, records what investigators observed during the inspection — it is not a finding that QuVa violated any regulation, and the company has 15 business days to respond before FDA’s Center for Drug Evaluation and Research decides whether the response is sufficient. What distinguishes this inspection is the site’s history: QuVa Pharma has one of the longest documented FDA inspection records among 503B outsourcing facilities, with 483s issued in 2016, 2017, 2019, 2022, and 2024, an FMD-145 letter in 2017, and an Untitled Letter issued June 18, 2025 — and observation 1 in this new 483 is explicitly marked by the investigator as “a repeat observation.”

A repeat observation on aseptic contamination-prevention procedures, cited under 21 CFR 211.113(b), less than a year after an Untitled Letter, is a meaningful signal about the trajectory of this site’s sterility assurance system. Observation 1 documents that a device used by technicians to pick items off the floor and place them in the trash inside ISO 7 cleanrooms had no defined disinfection frequency or designated storage location — instead, it was hung on the same cart used to hold drug components, utensils, and finished product containers; that a “black residue” was observed on that same cart during the walkthrough, indicating the cart itself was not being adequately cleaned and disinfected; and that dynamic smoke studies for the ISO 5 laminar airflow hoods and biological safety cabinets did not adequately assess airflow patterns under actual production setup, component placement, or maximum fill loads. Each of these findings, on its own, might be treated as an isolated procedural gap; documented as a repeat of a prior finding, it instead indicates that whatever corrective action followed the earlier observation did not durably change practice on the floor.

What the Record Documents

FDA’s 2004 Aseptic Processing Guidance treats the dynamic smoke study as one of the more consequential qualification exercises a sterile compounder performs, precisely because it is the mechanism that demonstrates first-air integrity is preserved once real components, containers, and human intervention are introduced into the ISO 5 critical zone — not just under static, empty-hood conditions. A smoke study that does not represent maximum drug-filled syringe or IV bag loads, or actual component placement, cannot support the conclusion that unidirectional airflow protects the critical zone during genuine production activity, which is the entire justification for classifying that zone as ISO 5 in the first place. Under FDA’s Grade A/ISO 5 environmental monitoring expectations, the smoke study result is what justifies relying on viable and non-viable particulate counts as evidence of aseptic control in the first place — a smoke study that has not actually demonstrated first-air integrity undermines the evidentiary basis for every subsequent environmental monitoring result collected in that hood.

Observation 2 turns to a specific contamination event, cited under 21 CFR 211.192: in November 2024, a compounding technician found a brown-to-black foreign residue on the ISO 5 laminar airflow hood grate in front of the installed High-Efficiency Particulate Air (HEPA) filter, later identified as heat-resistant sealant used in HEPA filter manufacturing, ahead of compounding a Fentanyl Citrate injectable lot. The unit was pulled from service, the filter replaced and recertified, and the affected line’s hood returned to service — but the 483 documents that QuVa could not provide sufficient evidence establishing when the filter degradation began, or whether other ISO 5 units across the facility’s other ISO 7 cleanroom suites might have been similarly affected and potentially released product compounded under degraded first-air conditions. An investigation that resolves the immediate unit without establishing the exposure window or scope across other units on the same equipment platform leaves open exactly the question 21 CFR 211.192 requires a firm to answer: was any other batch potentially affected by the same root cause?

Technical and Quality Context

Sites with a multi-cycle 483 history, an escalating compliance-communication ladder — 483 to Untitled Letter to repeat 483 — and a persistent inability to fully close aseptic-technique findings are, in FDA’s own pattern, at meaningfully elevated risk of a Warning Letter at the next inspection if the repeat finding surfaces again. The absence of a classic Warning Letter to date at this site should not be read as low risk; an Untitled Letter followed within a year by a repeat-observation 483 is itself an escalation step, not a plateau. It is also worth noting that FDA’s own escalation signals treat a repeat citation of the same CFR section as an independent trigger for heightened scrutiny, separate from the raw observation count; this 483 satisfies that criterion even though it carries only three total observations, which illustrates that observation count alone is a poor proxy for escalation risk.

Other aseptic manufacturers and 503B facilities should treat this 483 as a prompt to verify two things independently of their own audit schedule: that every reusable item entering the ISO 5/ISO 7 environment — including ancillary tools like floor-cleanup devices and carts — has a documented, followed disinfection frequency and dedicated storage location, and that dynamic smoke studies are refreshed whenever component types, fill volumes, or intervention patterns change, rather than treated as a one-time qualification exercise.

Decision Relevance

XGene Consulting helps 503B outsourcing facilities and sterile manufacturers redesign smoke study protocols, strengthen root-cause investigations for equipment-related contamination events, and prepare defensible responses to repeat-observation findings before they progress further up FDA’s compliance-communication ladder. If your site has a finding that has recurred across inspections, the corrective action that closed it the first time is worth re-examining now.